In summary, we have shown in this study that domatinostat, at clinically relevant concentrations, reduces the expression of FOXM1 and its transcriptional target survivin, and accordingly the viability of ovarian cancer cells alone and in combination with chemotherapeutic agents. Here, BIRC5 is linked to ovarian carcinoma.